Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TERN
- Price
- 3.06
- Stock movement up
- +0.05 (1.66%)
- Company name
- Terns Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 259.91M
- Ent value
- 3.54M
- Price/Sales
- 196.61
- Price/Book
- 0.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -47.78%
- 3 year return
- 26.83%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-05-29
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TERN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 196.61 |
| Price to Book | 0.71 |
| EV to Sales | 2.68 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 84.94M |
| EPS (TTM) | -1.13 |
| FCF per share (TTM) | -0.96 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.32M |
| Gross profit (TTM) | 626.00K |
| Operating income (TTM) | -99.98M |
| Net income (TTM) | -88.07M |
| EPS (TTM) | -1.13 |
| EPS (1y forward) | -1.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 47.35% |
| Operating margin (TTM) | -7562.78% |
| Profit margin (TTM) | -6662.10% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 270.14M |
| Net receivables | 0.00 |
| Total current assets | 376.51M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 378.23M |
| Accounts payable | 1.79M |
| Short/Current long term debt | 1.30M |
| Total current liabilities | 11.41M |
| Total liabilities | 13.76M |
| Shareholder's equity | 364.47M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -74.75M |
| Capital expenditures (TTM) | 86.00K |
| Free cash flow (TTM) | -74.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -24.16% |
| Return on Assets | -23.29% |
| Return on Invested Capital | -24.15% |
| Cash Return on Invested Capital | -20.52% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.02 |
| Daily high | 3.17 |
| Daily low | 3.00 |
| Daily Volume | 483K |
| All-time high | 27.25 |
| 1y analyst estimate | 19.06 |
| Beta | -0.33 |
| EPS (TTM) | -1.13 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| TERN | S&P500 | |
| Current price drop from All-time high | -88.77% | -4.11% |
| Highest price drop | -94.50% | -56.47% |
| Date of highest drop | 20 May 2022 | 9 Mar 2009 |
| Avg drop from high | -71.57% | -11.06% |
| Avg time to new high | 108 days | 12 days |
| Max time to new high | 1053 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
259.91M
Marketcap category
Small-cap
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Employees
66
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page